- Home
- ASPI vs DNA Comparison
ASPI vs DNA Comparison
Compare ASPI & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- DNA
- Stock Information
- Founded
- ASPI 2021
- DNA 2008
- Country
- ASPI United States
- DNA United States
- Employees
- ASPI N/A
- DNA N/A
- Industry
- ASPI Major Chemicals
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASPI Industrials
- DNA Health Care
- Exchange
- ASPI Nasdaq
- DNA Nasdaq
- Market Cap
- ASPI 470.6M
- DNA 466.4M
- IPO Year
- ASPI 2022
- DNA N/A
- Fundamental
- Price
- ASPI $5.52
- DNA $7.27
- Analyst Decision
- ASPI Strong Buy
- DNA Sell
- Analyst Count
- ASPI 2
- DNA 5
- Target Price
- ASPI $4.50
- DNA $17.25
- AVG Volume (30 Days)
- ASPI 1.9M
- DNA 1.3M
- Earning Date
- ASPI 05-19-2025
- DNA 05-06-2025
- Dividend Yield
- ASPI N/A
- DNA N/A
- EPS Growth
- ASPI N/A
- DNA N/A
- EPS
- ASPI N/A
- DNA N/A
- Revenue
- ASPI $4,144,225.00
- DNA $227,043,000.00
- Revenue This Year
- ASPI $690.06
- DNA N/A
- Revenue Next Year
- ASPI $93.09
- DNA $16.74
- P/E Ratio
- ASPI N/A
- DNA N/A
- Revenue Growth
- ASPI 857.04
- DNA N/A
- 52 Week Low
- ASPI $1.86
- DNA $5.00
- 52 Week High
- ASPI $9.33
- DNA $40.40
- Technical
- Relative Strength Index (RSI)
- ASPI 51.93
- DNA 43.40
- Support Level
- ASPI $5.16
- DNA $6.42
- Resistance Level
- ASPI $5.95
- DNA $7.71
- Average True Range (ATR)
- ASPI 0.44
- DNA 0.55
- MACD
- ASPI -0.04
- DNA -0.08
- Stochastic Oscillator
- ASPI 40.00
- DNA 16.59
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.